The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

The FDA has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a ...

In Singapore, GLP-1s such as Wegovy and Saxenda have been approved for weight-loss treatment. Patients can obtain them only ...

These include Wegovy, Saxenda, and Zepbound. Wegovy (semaglutide) is a GLP-1 receptor agonist that’s FDA-approved specifically for weight loss in certain people living with obesity. Wegovy is a ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration ...

Novo Nordisk’s net profit of $3.94bn represents a 21% increase from Q3 2023. Net sales in the quarter jumped by the same ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...

Novo Nordisk has reported net Q3 profits of $3.94bn (DKr27.3bn) fuelled by better-than-expected sales for its blockbuster weight loss drug Wegovy (semaglutide). Sales of the glucagon-like peptide ...